NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Service: Trial Number:
897-10
Principal Investigator: Conducted at:
Long Beach Medical Center
Currently enrolling additional patients:
Yes
Age Range:
18 & older
Gender:
Female

This study is being done to compare the effects, good and/or bad, of adding the drug trastuzumab (also called Herceptin) to breast radiation therapy. Radiation therapy is the standard treatment for patients with DCIS.

This study will find out if adding trastuzumab to breast radiation therapy is more effective than radiation therapy without trastuzumab in preventing occurrence of breast cancer in the same breast, in the other breast, or in other parts of the body in patients with HER2-positive DCIS.